Screener
Aurinia Pharmaceuticals AUPH Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 90.4%+0.8pp | 89.7%+1.5pp | 88.5%+0.5pp | 88.9%+1.7pp | 89.5%+3.4pp | |
| Operating margin | 48.4%+28.4pp | 41.7%+29.4pp | 37.1%+39.1pp | 26.3%+41.2pp | 20%+49.3pp | |
| Net margin | 100.8%+77.5pp | 100%+83.9pp | 101.5%+99.0pp | 29.3%+39.5pp | 23.3%+47.6pp | |
| Returns | ||||||
| Return on equity | 66.1%+48.8pp | 65%+53.8pp | 59.9%+58.4pp | 20.7%+26.4pp | 17.3%+30.6pp | |
| Return on invested capital | 33.7%+20.8pp | 25.2%+17.3pp | 21.4%+22.5pp | 16.7%+23.9pp | 12.8%+27.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.4×0.0× | 0.5×+0.1× | 0.5×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.4×+0.2× | 5.5×-0.4× | 5.2×+0.7× | 5.8×+0.2× | 5.2×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.2× | 0.2×-0.1× | 0.2×-0.1× | 0.3×0.0× | 0.3×0.0× | |
| Net debt / EBITDA | -0.6×-1.2× | 0.3×-0.2× | 0.1×-0.6× | 0.2×— | 0.6×— | |
| Per Share | ||||||
| Book value per share | $4.60+88.9% | $4.12+68.6% | $4.19+62.3% | $2.69+1.0% | $2.44-3.6% | |
| Valuation | ||||||
| Market capitalization | $2.07B+35.7% | $1.97B+78.5% | $2.1B+63.6% | $1.45B+38.7% | $1.09B+33.2% | |
| Price / earnings | 6.6×-18.6× | 6.6×-21.1× | 7.3×-216× | 18.7×— | 17.9×— | |
| Price / sales | 6.7×+0.8× | 6.6×+2.1× | 7.4×+2.0× | 5.5×+0.7× | 4.2×+0.2× | |
| Price / book | 3.4×-1.2× | 3.5×+0.3× | 3.6×+0.2× | 4×+1.3× | 3.2×+1.0× | |
| EV / EBITDA | 11.6×-10.4× | 14×-8.7× | 17×-70.8× | 16.5×— | 15.8×— |
FAQ
- What are Aurinia Pharmaceuticals's profit margins?
- Aurinia Pharmaceuticals (AUPH) runs a 90.4% gross margin and a 48.4% operating margin, with a 100.8% net margin.
- Where do Aurinia Pharmaceuticals's ratios come from?
- Every ratio is computed from Aurinia Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
